Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Body Compartment Pharmacokinetics of Anti-retroviral Agents That May be Used for Future HIV Post-exposure Prophylaxis Regimens.

Next Previous
Trial Profile

Body Compartment Pharmacokinetics of Anti-retroviral Agents That May be Used for Future HIV Post-exposure Prophylaxis Regimens.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 26 May 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide (Primary) ; Darunavir (Primary)
  • Indications HIV infections
  • Focus Pharmacokinetics
  • Acronyms PEP2

    • Most Recent Events

    • 19 May 2021 Results examining penile distribution of Cobicistat/elvitegravir/emtricitabine/tenofovir-alafenamide and Darunavir by testing urethral and glans surface swabs collected following a single oral dose, published in the Journal of Antimicrobial Chemotherapy
    • 26 Aug 2020 Status changed from recruiting to completed.
    • 06 Feb 2019 Planned End Date changed from 15 Jan 2019 to 15 Dec 2019.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top